Blog

Gregory Mercurio joins Lylon Precision Oncology as Chief Business Development and Strategy Officer

Gregory Mercurio/LinkedIn

Nov 24, 2024, 18:37

Gregory Mercurio joins Lylon Precision Oncology as Chief Business Development and Strategy Officer

Sendurai Mani, Dean’s Chair for Translational Oncology at Brown University Warren Alpert Medical School, shared a post on LinkedIn:

“Mr. John Tarantino, CEO of Iylon Precision Oncology, and the entire Iylon (www.iylon.com) team are honored to welcome Mr. Gregory Mercurio Jr. as Chief Business Development and Strategy Officer. Greg, a recognized leader in medical devices and healthcare, has been transforming the industry since 1983.

Greg is a President of Biotechnology Integration and Management; in this role, he has pioneered partnerships across healthcare facilities, technology providers, and patient treatment centers. His notable tenure includes serving as a Business Development Consultant at 21st Century Oncology, once the world’s largest radiology provider, and securing ground breaking Certificates of Need to establish joint ventures with Rhode Island’s major hospitals for advanced cancer treatment.

As a founding member of the Rhode Island PET/CT Mobile Imaging Network, Greg has provided life-changing cancer staging for over 20,000 patients. His 30 years of experience have shaped his belief in a ‘comprehensive, coordinated continuum of care,’ a philosophy that aligns perfectly with Iylon’s mission to educate and advance precision cancer care. This shared commitment makes Greg an invaluable addition to our leadership team.”

Sendurai Mani

Sendurai A. Mani is an Indian-American oncologist and molecular biologist. Currently holding the Dean’s Chair for Translational Oncology at Brown University Warren Alpert Medical School, Dr. Mani also serves as the Associate Director for Translational Oncology at the Legorreta Cancer Center at Alpert Medical School.